A Drug for Weight Loss and Smoking That Really Works?

At the American College of Cardiology Scientific Sessions scheduled to take place in early March, among the most anticipated studies to be presented are those involving rimonabant (trade name: Acomplia, from Sanofi-Synthelabo).

Rimonabant is the first of a new class of drugs that block the cannaboid receptor 1 (CB1). The CB1 receptor is thought to play an important role in certain aspects of human behavior and metabolism - specifically, it is thought to play a role in obesity, smoking habits, and lipid and glucose metabolism. Read more...